Updated:
Mediphase Venture Partners
Mediphase Venture Partners invests in healthcare and life sciences innovation, though operational details remain unconfirmed.
Mediphase Venture Partners
Mediphase Venture Partners is a venture capital firm focused on health care and life sciences investments. The firm has made 47 investments, including an option/warrant in Custom Ink on April 9, 2015. Mediphase Venture Partners has 15 portfolio exits, with Custom Ink being one of them, exiting on May 4, 2019.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What does Mediphase Venture Partners invest in?
The firm's name indicates a focus on medical and healthcare innovation, typically spanning biotechnology, medical devices, diagnostics, and digital health. However, the firm has not published a specific investment mandate or sector-exclusion list in public records.
Who makes investment decisions at Mediphase Venture Partners?
No principals, managing directors, or investment committee members have been publicly identified. The firm's leadership structure remains unconfirmed.
How large is Mediphase Venture Partners by assets or team size?
Mediphase has not disclosed assets under management, fund sizes, or team headcount. No regulatory filings or press reports have established these metrics.
Is Mediphase Venture Partners currently investing out of an active fund?
There is no public record of a fund close, open vehicle, or active deployment period. The firm's fundraising history is undocumented.
Where is Mediphase Venture Partners located?
A headquarters location or additional office has not been publicly established for Mediphase Venture Partners.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: